

Azithromycin

Section

Watch group antibiotics

- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

Trachoma

Cholera

Cholera [children]

Paratyphoid fever

Chlamydia trachomatis

Typhoid fever

Yaws

co-prescribed with ceftriaxone

Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

Cefepime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefixime

Section

Watch group antibiotics

- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Bacterial meningitis

Inflammatory and other diseases of prostate (severe)

Acute pyelonephritis (severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Bacterial pneumonia (Community-acquired pneumonia - severe)

Peritoneal abscess (mild-moderate)

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Peritonitis (mild-moderate)

Peritonitis (severe)

Second choice

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Bacterial infection of joint

Osteomyelitis or osteitis

Other indications

Bacterial infection of unspecified site

Ceftazidime

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

Endophthalmitis

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Section

Watch group antibiotics

- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Inflammatory and other diseases of prostate (severe)

Bacterial meningitis

Acute pyelonephritis (severe)

Paratyphoid fever

Gonococcal infection

Typhoid fever

Peritonitis (mild-moderate)

Peritonitis (severe)

Peritoneal abscess (mild-moderate)

Peritoneal abscess (severe)

Endophthalmitis

Bacterial pneumonia (Community-acquired pneumonia - severe)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with metronidazole

Necrotising fasciitis

Second choice

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Bacterial infection of joint

Sepsis without septic shock

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Ciprofloxacin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

Acute pyelonephritis (mild to moderate)

Infectious gastroenteritis or colitis without specification of infectious agent

Paratyphoid fever

Typhoid fever

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Second choice

Cholera

Cholera [children]

Peritonitis (mild-moderate)

Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Clarithromycin

Section

Watch group antibiotics

- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg

Indications

First choice

co-prescribed with [cefotaxime](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescribed with [ceftriaxone](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Second choice

[Acute pharyngitis](#)

co-prescribed with [amoxicillin + clavulanic acid](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

Other indications

[Helicobacter pylori associated gastric ulcer](#)

Delafloxacin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg

Indications

[Methicillin resistant Staphylococcus aureus](#)

Erythromycin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to [clarithromycin](#) for

[Acute pharyngitis](#)

Other indications

[Bacterial infection of unspecified site](#)

Flomoxef

Section

Watch group antibiotics

- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified other antibiotic resistant Enterobacterales](#)

Fourth generation cephalosporins

Section

Watch group antibiotics

- .

Indications

Other specified bacterial diseases

Imipenem + cilastatin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to [meropenem](#) for

Peritonitis (severe)

Therapeutic equivalent to [meropenem](#) for

Peritoneal abscess (severe)

Therapeutic equivalent to [meropenem](#) for

Neutropenia (high-risk)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Meropenem

Section

Watch group antibiotics

- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neonatal meningitis

Peritonitis (severe)

Peritoneal abscess (severe)

Neutropenia (high-risk)

Piperacillin + tazobactam

Section

Watch group antibiotics

- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Neutropenia (high-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Peritonitis (severe)

Peritoneal abscess (severe)

co-prescribed with clindamycin

Necrotising fasciitis

Vancomycin

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

Necrotising fasciitis

co-prescribed with ceftazidime

Endophthalmitis

co-prescribed with ceftriaxone

Endophthalmitis

Second choice

Intestinal infections due to *Clostridioides difficile*

Neutropenia (high-risk)

Other indications

Methicillin resistant *Staphylococcus aureus*